Our results demonstrate that elevated ET-1 in the acute phase of Covid-19 infection is a clinical feature unique to severe disease, supporting the hypothesis [8] that endothelin receptor antagonists, used to treat pulmonary arterial hypertension, may be beneficial in a subset of Covid-19 patients. The gene discussed is EDN1; the disease is pulmonary arterial hypertension.